DMRADamora Therapeutics, Inc.
$21.12+636% 1Y
$21.12
$3.0052 weeks$34.14
Is the price fair?
What DMRA's price assumes
Damora Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 169× revenue.
169
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 2.67
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 2.67
- EV / EBIToperating margin −3312%: the multiple describes the denominator
- not meaningful
- Market capitalisation
- $1.39B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks